| Literature DB >> 30709384 |
Claudia S E W Schuurhuizen1,2, Annemarie M J Braamse3, Inge R H M Konings1, Henk M W Verheul1, Joost Dekker4.
Abstract
BACKGROUND: Patients with advanced disease experience high levels of psychological distress, yet there is low uptake of psychosocial services offered to patients who screened positive for distress. In this study we aimed to identify predictors for use of psychosocial services in patients with metastatic colorectal cancer (mCRC) receiving first line chemotherapy enrolled in a prospective cluster randomized trial (CRT).Entities:
Keywords: Metastatic colorectal cancer; Palliative treatment; Predictors; Psychosocial services
Mesh:
Year: 2019 PMID: 30709384 PMCID: PMC6359772 DOI: 10.1186/s12885-019-5318-9
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Results of univariable analyses on demographic, clinical and psychosocial baseline variables
| No use of psychosocial support services ( | Use of psychosocial support services ( |
| |
|---|---|---|---|
| Age, years | *0.003 | ||
| Mean age (SD) | 66.92 (9.7) | 62.74 (11.41) | |
| Gender | 0.415 | ||
| Male | 182 (65.2) | 42 (60.0) | |
| Female | 97 (34.8) | 28 (40.0) | |
| Treatment arm in TES trial | 0.610 | ||
| Intervention | 149 (53.4) | 35 (50) | |
| Control | 130 (46.6) | 35 (50) | |
| ECOG PSa | 0.714 | ||
| 0 | 67 (24.0) | 15 (21.4) | |
| 1 | 87 (31.2) | 18 (25.7) | |
| 2 | 8 (2.9) | 3 (4.3) | |
| Missing | 117 (41.9) | 34 (48.6) | |
| Primary tumor location | 0.695 | ||
| Right-sided | 84 (30.1) | 23 (32.9) | |
| Left-sided | 192 (68.8) | 47 (67.1) | |
| Missing | 3 (1.1) | – | |
| Chemotherapy regimen | 0.875 | ||
| Capecitabine | 59 (21.1) | 13 (18.6) | |
| CAPOX | 190 (68.1) | 50 (71.4) | |
| FOLFOX/Other | 27 (9.7) | 7 (10.0) | |
| Missing | 3 (1.1) | – | |
| Number of comorbidities | 0.980 | ||
| Mean (SD) | 2.33 (1.78) | 2.33 (2.00) | |
| Marital status | 0.369 | ||
| Married/domestic partnership | 207 (74.2) | 49 (70.0) | |
| Unmarried/divorced/widowed | 68 (24.4) | 21 (30.0) | |
| Missing | 4 (1.4) | – | |
| Number of persons in household | 0.615 | ||
| 1 | 49 (17.6) | 13 (18.6) | |
| 2 | 177 (63.4) | 42 (60.0) | |
| 3 | 23 (8.2) | 4 (5.7) | |
| > 3 | 26 (9.3) | 11 (15.7) | |
| Missing | 4 (1.4) | – | |
| Educationb | *0.041 | ||
| Low | 17 (6.1) | 2 (2.9) | |
| Middle | 184 (65.9) | 39 (55.7) | |
| High | 72 (25.8) | 29 (41.4) | |
| Missing | 6 (2.2) | 0 (0) | |
| Currently working | 0.949 | ||
| Yes | 65 (23.3) | 16 (22.9) | |
| No/retired | 210 (75.3) | 54 (77.1) | |
| Missing | 4 (1.4) | – | |
| Time from diagnosis primary tumor until start study | 0.848 | ||
| < 1.5 months | 94 (33.7) | 22 (31.4) | |
| 1.5–10 months | 89 (31.9) | 25 (35.7) | |
| > 10 months | 93 (33.3) | 23 (32.9) | |
| Missing | 3 (1.1) | – | |
| Time from diagnosis metastatic disease until start study | 0.666 | ||
| < 1.0 months | 95 (34.1) | 27 (38.6) | |
| 1.0–2.5 months | 87 (31.2) | 23 (32.9) | |
| > 2.5 months | 94 (33.7) | 20 (28.6) | |
| Missing | 3 (1.1) | – | |
| Prior cancer related treatment | |||
| No | 85 (30.5) | 23 (32.9) | 0.699 |
| Yes | 194 (69.5 | 47 (67.1) | |
| Prior treatment metastases | |||
| No | 214 (76.7) | 56 (80.0) | 0.657 |
| Yes | 62 (22.2) | 14 (20.0) | |
| Missing | 3 (1.1) | – | |
| Number of organs with metastases | 0.599 | ||
| Median | 2 | 2 | |
| Total number of metastases | |||
| Median | 11.5 | 13.0 | 0.877 |
| Participation in other trials | 0.718 | ||
| No | 170 (60.9) | 41 (58.6) | |
| Yes | 109 (39.1) | 29 (41.4) | |
| HADS | |||
| Total score | 9.10 (6.30) | 11.17 (7.47) | *0.020 |
| Distress on HADS No | 208 (74.6) | 44 (62.9) | *0.033 |
| Yes | 67 (24.0) | 26 (37.1) | |
| Missing | 4 (1.4) | – | |
| DT/PL | |||
| DT score | 4.33 (2.68) | 4.75 (2.40) | *0.242 |
| Total of physical problems | 5.78 (6.29) | 7.37 (4.61) | *0.020 |
| Total of emotional problems | 1.95 (2.11) | 2.74 (2.57) | *0.009 |
| Need to talk to professional No | 257 (92.1) | 58 (82.9) | *0.023 |
| Yes | 22 (7.9) | 12 (17.1) | |
| Quality of life (QLQ-C30) | |||
| Physical functioning | 74.84 (20.30) | 72.76 (21.88) | 0.451 |
| Role functioning | 65.69 (30.70) | 58.81 (30.13) | *0.010 |
| Emotional functioning | 78.25 (18.12) | 72.86 (21.41) | *0.095 |
| Cognitive functioning | 89.44 (14.97) | 86.90 (16.76) | *0.219 |
| Social functioning | 78.08 (23.89) | 69.05 (31.38) | *0.010 |
| Global QOL | 63.77 (21.73) | 60.00 (21.78) | *0.197 |
| Pain score | 16.00 (23.75) | 40.15 (26.57) | *0.174 |
| Fatigue score | 25.00 (16.67) | 45.08 (44.44) | *0.009 |
Abbreviations: SD standard deviation, ECOG PS Eastern Cooperative Oncology Group Performance Status, HADS Hospital Anxiety and Depression Scale, DT/PL Distress Thermometer and Problem list, QLQ-C30 Quality of Life Questionnaire-C30. *Characteristics were included in the multivariate model if they had an univariable association (p ≤ .25). aECOG PS 0: Fully active, able to carry on all pre-disease performance without restriction. ECOG PS 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. ECOG PS 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. bLow: primary education, middle: lower general secondary education, intermediate vocational education or high school, high: higher vocational education or university
Univariable analyses for clinical variables during treatment predictive for the use of psychosocial support services
| No use of psychosocial support services (n = 279)(n,%) | Use of psychosocial support services (n = 70)(n,%) |
| |
|---|---|---|---|
| Progression of disease within first 10 weeks of treatment | *0.089 | ||
| No | 242 (86.7) | 66 (94.3) | |
| Yes | 37 (13.3) | 4 (5.7) | |
| Progression of disease during follow up | 0.289 | ||
| No | 93 (33.3) | 28 (40.0) | |
| Yes | 186 (66.7) | 42 (60.0) | |
| Total number of grade 3–4 AEs during 48 weeks follow up | 1.64 (2.12) | 2.06 (2.65) | *0.166 |
| Total number of admissions during 48 weeks follow up | 1.79 (1.34) | 2.13 (1.98) | *0.216 |
Abbreviations: AEs adverse events. *Characteristics were included in the multivariate model if they had an univariable association (p ≤ .25)
Final multivariable model of baseline predictors
| Predictive factora | Wald | Odds Ratio | 95% C.I.for EXP(B) | VIF | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Need to talk to professional | 4.451 | .035 | 2.360 | 1.063 | 5.240 | 1.010 |
| Pain score at baseline | 8.053 | .005 | 1.015 | 1.005 | 1.025 | 1.009 |
| Age | 8.066 | .005 | .963 | .938 | .988 | 1.022 |
| Education | 5.823 | .054 | 1.031 | |||
| Middle compared to low | .084 | .772 | 1.255 | .270 | 5.837 | |
| High compared to low | 1.340 | .247 | 2.518 | .527 | 12.024 | |
Abbreviations: OR odds ratio, VIF variable inflation factor. aPredictive factors were statistically significant at the least at the 0.10 level
Final multivariable model of baseline predictors and clinical predictors
| Predictive factora | Wald | Odds Ratio | 95% C.I.for EXP(B) | VIF | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Need to talk to professional | 4.712 | .030 | 2.429 | 1.090 | 5.412 | 1.010 |
| Pain score at baseline | 9.895 | .002 | 1.017 | 1.006 | 1.028 | 1.030 |
| Age | 6.938 | .008 | .965 | .940 | .991 | 1.030 |
| Education | 6.190 | .045 | 1.033 | |||
| Middle compared to low | .128 | .720 | 1.327 | .283 | 6.229 | |
| High compared to low | 1.558 | .212 | 2.729 | .564 | 13.204 | |
| Progression within first 10 weeks of treatment | 4.136 | .042 | .314 | .103 | .959 | 1.029 |
Abbreviations: OR odds ratio, VIF variable inflation factor. aPredictive factors were statistically significant at the least at the 0.10 level